Cansino Biologics Inc (688185) - Total Liabilities

Latest as of September 2025: CN¥2.37 Billion CNY ≈ $346.78 Million USD

Based on the latest financial reports, Cansino Biologics Inc (688185) has total liabilities worth CN¥2.37 Billion CNY (≈ $346.78 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688185 cash flow metrics to assess how effectively this company generates cash.

Cansino Biologics Inc - Total Liabilities Trend (2016–2024)

This chart illustrates how Cansino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Cansino Biologics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Cansino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Cansino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Henan Hengxing Science & Technology Co Ltd SHE:002132	China	CN¥4.80 Billion
Sinoseal Holding Co Ltd SHE:300470	China	CN¥676.08 Million
Zhe Jiang Kangsheng Co Ltd SHE:002418	China	CN¥1.62 Billion
BP PLC LSE:BP	UK	GBX204.53 Billion
Shenzhen Anche Technologies Co Ltd SHE:300572	China	CN¥676.40 Million
Cymbria Corporation TO:CYB	Canada	CA$162.14 Million
Shanghai Research Institute of Building Sciences Group Co. Ltd A SHG:603153	China	CN¥1.79 Billion
Shandong Fengyuan Chemical Co Ltd SHE:002805	China	CN¥2.86 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Cansino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688185 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.62	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cansino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cansino Biologics Inc (2016–2024)

The table below shows the annual total liabilities of Cansino Biologics Inc from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥3.05 Billion ≈ $446.06 Million	-24.39%
2023-12-31	CN¥4.03 Billion ≈ $589.91 Million	-4.55%
2022-12-31	CN¥4.22 Billion ≈ $618.01 Million	+26.97%
2021-12-31	CN¥3.33 Billion ≈ $486.74 Million	+391.17%
2020-12-31	CN¥677.22 Million ≈ $99.10 Million	+115.69%
2019-12-31	CN¥313.98 Million ≈ $45.95 Million	+6.96%
2018-12-31	CN¥293.56 Million ≈ $42.96 Million	+13.33%
2017-12-31	CN¥259.03 Million ≈ $37.90 Million	+131.90%
2016-12-31	CN¥111.70 Million ≈ $16.35 Million	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.03 Billion

CN¥7.04 Billion CNY

Market Cap Rank

#9007 Global

#2413 in China

Share Price

CN¥61.59

Change (1 day)

+0.13%

52-Week Range

CN¥55.60 - CN¥88.48

All Time High

CN¥773.75